How should Movantik (methylnaltrexone bromide) be started and dosed for opioid‑induced constipation, and what are its contraindications, common adverse effects, and monitoring recommendations?

Movantik (Naloxegol) for Opioid-Induced Constipation

Critical Clarification

The question asks about "Movantik" but this is the brand name for naloxegol, NOT methylnaltrexone bromide. Methylnaltrexone is marketed as Relistor. The evidence provided primarily discusses methylnaltrexone, which is a different PAMORA (peripherally acting mu-opioid receptor antagonist) than Movantik.

Dosing and Administration for Movantik (Naloxegol)

Start Movantik at 25 mg once daily on an empty stomach (at least 1 hour before or 2 hours after the first meal); reduce to 12.5 mg once daily if the 25 mg dose is not tolerated 1.

Key Administration Requirements:

• Discontinue all maintenance laxatives before starting Movantik—you may resume them only if OIC symptoms persist after 3 days of treatment 1
• Take on an empty stomach: at least 1 hour before breakfast or 2 hours after meals 1
• Avoid grapefruit and grapefruit juice completely (increases drug levels via CYP3A4 inhibition) 1
• No need to adjust opioid doses before starting 1
• Patients on opioids for less than 4 weeks may respond poorly 1
• Stop Movantik if opioid therapy is discontinued 1

Dose Adjustments:

• Renal impairment (CrCl <60 mL/min): Start at 12.5 mg once daily; may increase to 25 mg if tolerated while monitoring closely for adverse effects 1
• Moderate CYP3A4 inhibitors (diltiazem, erythromycin, verapamil): Reduce to 12.5 mg once daily if concomitant use is unavoidable 1

Contraindications

Movantik is absolutely contraindicated in three situations 1:

1. Known or suspected gastrointestinal obstruction and patients at risk for recurrent obstruction
2. Concomitant use with strong CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole)
3. Known serious or severe hypersensitivity reaction to naloxegol or its excipients

Common Adverse Effects

The most common adverse reactions (≥3% incidence) are 1:

• Abdominal pain (most common)
• Diarrhea
• Nausea
• Flatulence
• Vomiting
• Headache

Serious Warnings:

• Severe abdominal pain and/or diarrhea: Monitor after initiation; discontinue if severe symptoms develop. May cautiously restart at 12.5 mg if appropriate 1
• GI perforation risk: Use extreme caution in patients with known or suspected GI tract lesions; monitor for severe, persistent, or worsening abdominal pain 1
• Opioid withdrawal: Consider risk-benefit in patients with disrupted blood-brain barrier; monitor for withdrawal symptoms (though peripheral selectivity minimizes this risk) 1

Monitoring Recommendations

Monitor for the following 1:

• Development of severe abdominal pain (may indicate perforation)
• Signs of opioid withdrawal (particularly in patients with compromised blood-brain barrier)
• Adverse reactions in renal impairment patients, especially when increasing from 12.5 mg to 25 mg
• Bowel movement response within 3 days to determine if laxatives need to be resumed

Guideline Context

The 2019 AGA guidelines recommend traditional laxatives as first-line therapy for OIC (strong recommendation, moderate quality evidence) 2. For laxative-refractory OIC, the AGA recommends naldemedine (strong) and naloxegol (strong, moderate quality evidence) over no treatment, while methylnaltrexone receives only a conditional recommendation with low-quality evidence 2. This positions Movantik (naloxegol) as a second-line agent after laxative failure, not as initial therapy.

Clinical Pitfalls:

• Do not use Movantik as first-line therapy—try traditional laxatives first per guidelines 2
• Do not continue maintenance laxatives when starting Movantik (common error) 1
• Do not use with strong CYP3A4 inhibitors—this is an absolute contraindication, not just a precaution 1
• Avoid in severe hepatic impairment 1